Table: Anges -2023 parent results
Feb 22 (Reuters)-
Anges, Inc.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2023 Dec 31, 2022 Dec 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 138 mln 67 mln
(+107.2 pct) (+4.5 pct)
Operating loss 4.80 loss 9.69
Recurring 1.99 loss 8.00
Net 1.07 loss 8.12
EPS 5.64 yen loss 52.00 yen
EPS Diluted 5.49 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001